Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.
Adamson, Karen Reid, Hazel Barnes, Dennis Sivappriyan, Siva Bickerton, Alex Gallen, Ian W Field, Benjamin C T Idris, Iskandar
Adamson, Karen
Reid, Hazel
Barnes, Dennis
Sivappriyan, Siva
Bickerton, Alex
Gallen, Ian W
Field, Benjamin C T
Idris, Iskandar
Citations
Altmetric:
Affiliation
University of Nottingham; University Hospitals of Derby and Burton NHS Trust; St John's Hospital; Sandwell & West Birmingham NHS Trust
Other Contributors
Publication date
2022-04-07
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure. The analysis, in this research letter, shows that decreases in HbA1c and weight associated with semaglutide occur irrespective of previous GLP-1RA use. However, HbA1c reductions were less if switched from dulaglutide or liraglutide and weight changes were attenuated if switched from dulaglutide or exenatide, potentially suggesting differing potencies between GLP-1RAs. Dedicated studies with head-to-head comparisons are needed to confirm these findings.
Citation
Crabtree, T. S. J., Adamson, K., Reid, H., Barnes, D., Sivappriyan, S., Bickerton, A., Gallen, I. W., Field, B. C. T., Idris, I., Ryder, R. E. J., & all ABCD semaglutide audit contributors (2022). Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists. Diabetes, obesity & metabolism, 24(7), 1398–1401. https://doi.org/10.1111/dom.14701
Type
Article